Merck and Moderna announce 42 percent reduction in melanoma recurrence risks

Merck and Moderna announced on Thursday that their collaborative personalized mRNA vaccine for melanoma has demonstrated a 42 percent reduction in the risk of death or cancer recurrence. The finding comes from a late-stage clinical trial and represents a major step forward in treating the deadliest form of skin cancer. The two pharmaceutical companies have already begun discussions with regulatory bodies to seek approval for the new therapy.

The trial data, which was initially set to be presented at the European Society of Medical Oncology conference currently underway in Madrid, Spain, was released ahead of schedule. An oncology news outlet reported the results early, breaking the embargo, which prompted the companies to issue a formal statement with the top-line figures. The complete dataset has been accepted for publication in the New England Journal of Medicine.

In August, both partners had confirmed that the vaccine met its primary endpoints in the study. However, they withheld specific details until the data could be formally presented at the scientific conference. The early release of the numbers underscores the significance of the results and the anticipation surrounding the potential approval of this novel approach to immunotherapy.

The Phase 3 study enrolled 1,137 patients who had stage IIB through IV melanoma. All participants had undergone surgical removal of their tumors before entering the trial. The study design randomized patients in a two-to-one ratio to receive either the personalized mRNA vaccine alongside standard care or the standard treatment alone. The standard of care in this context was Merck’s established monoclonal antibody, Keytruda.

Stéphane Bancel, the chief executive officer of Moderna, highlighted the long-term vision behind the technology in a statement. He noted that the company believed from the outset that mRNA technology could enable the development of treatments uniquely matched to an individual’s specific tumor. The results, he said, mark a defining moment for that vision and demonstrate the possibilities that arise when the manufacturing of medicines is reimagined.

Bancel added that the findings reinforce the company’s conviction that mRNA platforms have the potential to fundamentally alter how cancer is treated. For patients and medical professionals, the success of this trial bolsters hope that individualized cancer-targeting medicines will become a new paradigm in oncology, moving beyond one-size-fits-all approaches to more precise and effective therapies.

The announcement positions the two companies at the forefront of the next wave of cancer therapies. By combining the rapid adaptability of mRNA with the proven efficacy of existing immunotherapies, Merck and Moderna are aiming to set a new standard of care for melanoma patients worldwide.